Study of immune system signals in IgG4-related disease
Treatments studied
Part of Immune system & allergy clinical trials.
This study looks at a specific immune signal (C5a) in people with IgG4-related disease to see if it could be a target for future treatments. It compares patients with active disease, those in remission, and healthy volunteers to understand how this signal changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with IgG4-related disease using the ACR/EULAR 2019 criteria.
- You have active disease with a score of at least 2 in at least one affected organ.
- You are not taking high-dose steroids (5 mg/day or more) or have stopped for at least 1 month.
- You are not on immunosuppressive therapy currently or within the last 3 months.
- You are not on biologic therapy currently or within the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called inebilizumab in children and teens with IgG4-related disease, a rare condition causing swelling and organ damage. The drug may help reduce the immune system attack that causes the disease. It may be an option if standard treatments haven't fully worked.
This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.
This trial tests whether a medication called lenalidomide helps keep your IgG4-related disease in remission and prevents it from coming back. It is for people whose disease is well controlled on low-dose steroids.
This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.
This trial is testing a new investigational drug called IMM0306 for people with IgG4-related disease, a condition where the body's immune system attacks its own organs. If you're currently needing steroids for a flare, this study might offer a new treatment option that could help control the disease with fewer side effects.
This study tests an investigational drug, ACE1831, in people with active IgG4-related disease (IgG4-RD), a condition where the immune system causes inflammation and swelling in organs. The purpose is to see if ACE1831 is safe and effective in reducing disease flare-ups, possibly offering a new treatment option.
Hear when a new Immunoglobulin G4-Related Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.